The Cushing’s Syndrome drugs in development market research report provides comprehensive information on the therapeutics under development for Cushing’s Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Cushing’s Syndrome. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Cushing’s Syndrome and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Cushing’s Syndrome by six companies/universities/institutes. The top development phase for Cushing’s Syndrome is preclinical with two drugs in that stage. The Cushing’s Syndrome pipeline has seven drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Cushing’s Syndrome pipeline products market are: SteroTherapeutics, Corcept Therapeutics and Recordati.
The key targets in the Cushing’s Syndrome pipeline products market include Glucose-6-Phosphate 1-Dehydrogenase (G6PD or EC 1.1.1.49), Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1), and Lanosterol 14 Alpha Demethylase (Sterol 14 Alpha Demethylase or Cytochrome P450 14DM or Cytochrome P450LI or Cytochrome P450 51A1 or CYPLI or CYP51A1 or EC 1.14.14.154).
The key mechanisms of action in the Cushing’s Syndrome pipeline product include Glucose-6-Phosphate 1-Dehydrogenase (G6PD or EC 1.1.1.49) Inhibitor with two drugs in Preclinical. The Cushing’s Syndrome pipeline products include three routes of administration with the top ROA being Oral and two key molecule types in the Cushing’s Syndrome pipeline products market including Small Molecule, and Antisense RNAi Oligonucleotide.
Cushing’s Syndrome overview
Cushing’s syndrome is a disorder that occurs when your body makes too much of the hormone cortisol over a long period of time. Cortisol is sometimes called the “stress hormone” because it helps your body respond to stress. This may be caused by a variety of factors like long-term use of corticosteroid medications, tumors in the pituitary gland or adrenal adenomas.
For a complete picture of Cushing’s Syndrome’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
